Who Generates Higher Gross Profit? Amneal Pharmaceuticals, Inc. or Travere Therapeutics, Inc.

Amneal vs. Travere: A Decade of Gross Profit Trends

__timestampAmneal Pharmaceuticals, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 201444963400027632226
Thursday, January 1, 201549922600097707000
Friday, January 1, 2016597455000129037000
Sunday, January 1, 2017526178000151332000
Monday, January 1, 2018716403000158719000
Tuesday, January 1, 2019352997000170104000
Wednesday, January 1, 2020628393000192195000
Friday, January 1, 2021768973000220706000
Saturday, January 1, 2022784708000204426000
Sunday, January 1, 2023820565000133788000
Loading chart...

Unleashing the power of data

A Tale of Two Pharmaceutical Giants: Amneal vs. Travere

In the competitive landscape of pharmaceuticals, Amneal Pharmaceuticals, Inc. and Travere Therapeutics, Inc. have been vying for dominance in gross profit generation over the past decade. From 2014 to 2023, Amneal consistently outperformed Travere, with its gross profit peaking at approximately 820 million in 2023, a staggering 500% increase from Travere's 134 million in the same year. This trend highlights Amneal's robust growth strategy and market penetration. Notably, Amneal's gross profit surged by 75% from 2014 to 2023, while Travere's increased by 384%, albeit from a much smaller base. The data underscores Amneal's stronghold in the industry, yet Travere's rapid growth trajectory suggests a promising future. As the pharmaceutical sector continues to evolve, these insights provide a glimpse into the financial health and strategic direction of these two key players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025